Results 61 to 70 of about 6,340 (200)

Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats

Pharmaceuticals, 2022
We have previously demonstrated that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) protects the liver via downregulation of hepatic matrix metalloproteinases (MMPs) after ischemia/reperfusion (I/R), which can lead to multiorgan ...
Giuseppina Palladini, Marta Cagna, Laura Giuseppina Di Pasqua, Luciano Adorini, Anna Cleta Croce, Stefano Perlini, Andrea Ferrigno, Clarissa Berardo, Mariapia Vairetti   +8 more
doaj   +1 more source

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016 [PDF]

, 2016
Absztrakt Az utolsó évtizedben a fejlett országokban a nem alkoholos zsírmáj lett a leggyakrabban diagnosztizált krónikus májbetegség.
Pár, Alajos, Pár, Gabriella
core   +1 more source

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
Seladelpar improved itch, itch‐related sleep disturbance and measures of fatigue in patients with primary biliary cholangitis and pruritus in the Phase 3 RESPONSE trial. ABSTRACT Background Pruritus and fatigue impose a significant burden on patient quality of life in primary biliary cholangitis (PBC).
Cynthia Levy, David E. J. Jones, Marlyn J. Mayo, Christopher L. Bowlus, Kris V. Kowdley, Gideon M. Hirschfield, Jie Liu, Caroline Burk, Susheela Carroll, Daria B. Crittenden, Andreas E. Kremer   +10 more
wiley   +1 more source

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

Drug Design, Development and Therapy, 2019
Dan-Ying Zhang,1,* Lin Zhu,2,* Hai-Ning Liu,1,* Yu-Jen Tseng,3 Shu-Qiang Weng,1 Tao-Tao Liu,1 Ling Dong,1 Xi-Zhong Shen1,41Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, People’s Republic of China ...
Zhang DY, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ   +7 more
doaj  

Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid [PDF]

, 2017
OBJECTIVES: We aimed to validate the prognostic models for primary biliary cholangitis (PBC) in Chinese patients receiving ursodeoxycholic acid (UCDA), and to compare their performances in predicting the long-term survival. METHODS: Chinese patients with
Cheung, KS, Fung, JYY, Lai, CL, Seto, WKW, Yuen, RMF   +4 more
core   +1 more source

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation

Alimentary Pharmacology &Therapeutics, EarlyView.
Among a nationwide population with primary biliary cholangitis, almost all people were prescribed ursodeoxycholic acid (UDCA). However, UDCA was insufficiently dosed in a one third of them. The results indicate that first‐line treatment can be optimized, particularly in those with a biochemical response and higher body weight.
Ellen Werner, Maria C. B. van Hooff, Gemma H. X. Weijsters, Maria A. van de Vrie, Rozanne C. de Veer, Ulrich Beuers, Joost P. H. Drenth, Frans J. C. Cuperus, Remco van Dijk, Bart J. Veldt, Michael Klemt‐Kropp, Suzanne van Meer, Robert C. Verdonk, Hajo J. Flink, Jan Maarten Vrolijk, Matthijs Kramer, Cyriel Y. Ponsioen, Kirsten Boonstra, Femke Boersma, Hendrik J. M. de Jonge, Frank H. J. Wolfhagen, L. C. Baak, Susanne L. Onderwater, Jeroen D. van Bergeijk, Paul G. van Putten, Gijs J. de Bruin, Rob P. R. Adang, Maria N. Aparicio‐Pages, Wink de Boer, Frank ter Borg, Hanneke van Soest, Elsemieke S. de Vries, Nicole S. Erler, Bettina E. Hansen, Harry L. A. Janssen, Adriaan J. van der Meer, on behalf of the Dutch PBC Study Group, Adriaan J. van der Meer, Anne Vrieze, A. (Sander) van der Beek, Bart J. Veldt, Bart van Hoek, Bettina E. Hansen, Cyriel Y. Ponsioen, Daphne M. Hotho, Djuna L. Cahen, Edith M.M. Kuiper, Ellen Werner, Elsemieke de Vries, Femke Boersma, Frank C. Bekkering, Frank H.J. Wolfhagen, Frank ter Borg, Frans J.C. Cuperus, Gemma X. Weijsters, Gijs J. de Bruin, Hajo J. Flink, Hanneke van Soest, Hans H.K. Thio, Harry L.A. Janssen, Hendrik J.M. de Jonge, Huseyin Aktas, Ingrid C.A.W. Konings, J. Marleen de Vree, J. (Netty) van Kemenade, Jan Maarten Vrolijk, Janne E. van Rooij, Jeroen D. van Bergeijk, Jerome Sint Nicolaas, Johan P.H. Kuyvenhoven, Johannes Schmidt‐Böhmer, Joost P.H. Drenth, Khalida Soufidi, Kirsten Boonstra, Laurens A. van der Waaij, L. (Bert) C. Baak, Leendert H. Oterdoom, Lisette J.H. van Dam, Ludger S.M. Epping, Paul J. Bus, Maaike J. Denters, Marcel Cazemier, Maria C. van Hooff, Maria N. Aparicio‐Pages, Marjo J. Kerbert‐Dreteler, Martijn J. ter Borg, Martine A.M.C. Baven‐Pronk, Matthias C. Jurgens, Matthijs Kramer, Menno Beukema, Merel M. Tielemans, Michael Klemt‐Kropp, Nicole F.M. van Gerven, Nicole S. Erler, Paul G. van Putten, Philip W. Friederich, Pieter C.J. ter Borg, Robert C. Verdonk, Remco van Dijk, Rob P.R. Adang, Robert Roomer, Rozanne C. de Veer, Sander de Kort, Sigrid Vandebosch, Stephan H.C. van Stiphout, Stephan Schmittgens, Sunje Abraham, Susanne L. Onderwater, Suzanne van Meer, Sven J. van den Hazel, Tiki D. Blom, Tim C.M.A. Schreuder, Tom J.G. Gevers, Ulrich Beuers, Ulrike de Wit, Wink de Boer, Yasser A. Alderlieste   +116 more
wiley   +1 more source

Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel SyndromeSummary

Cellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Options for the prevention of short-bowel syndrome–associated liver disease (SBS-ALDs) are limited and often ineffective. The farnesoid X receptor (FXR) is a newly emerging pharmaceutical target and FXR agonists have been shown to ...
Prue M. Pereira-Fantini, Susan Lapthorne, Cormac G.M. Gahan, Susan A. Joyce, Jenny Charles, Peter J. Fuller, Julie E. Bines   +6 more
doaj   +1 more source

Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease [PDF]

, 2017
BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).
Fox, Ryan
core  

Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. [PDF]

, 2017
This study aims to uncover how specific bacteria and bile acids (BAs) contribute to steatosis induced by diet and farnesoid X receptor (FXR) deficiency in both genders.
French, Samuel W, Gonzalez, Frank J, Jena, Prasant Kumar, Kalanetra, Karen M, Krishnan, Viswanathan V, Liu, Hui-Xin, Mills, David A, Sheng, Lili, Wan, Yu-Jui Yvonne   +8 more
core   +1 more source

Hepatocyte TrkB Acts as a Gatekeeper Against MASH‐Related Liver Fibrosis by Suppressing the TGFβ/CCL2 Axis and Macrophage Infiltration

Cell Proliferation, EarlyView.
Hepatocyte TrkB is identified as a critical gatekeeper against MASH‐related fibrosis. Mechanistically, TrkB inhibits the TGFβ/SMAD3/FOS axis to suppress CCL2 secretion, thereby blocking pathogenic macrophage recruitment and ameliorating liver fibrosis.
Yueying Chen, Jiayi Wei, Shuxuan Li, Kefan Yin, Heming Wang, Yicheng Zhao, Shuqiang Weng, Xizhong Shen, Guangqi Song, Changfeng Zhu, Qunyan Yao, Ling Dong   +11 more
wiley   +1 more source